Lifecore Biomedical Inc. - LFCR Net Assets per Single Share

The daily price chart for Lifecore Biomedical (LFCR) reflects the asset's dynamics, with its value currently at -0.90. The business relies on predictive reagent inventory control to eliminate downtime, while operational activities remain heavily dependent on external biomaterial suppliers. The company's high standing is confirmed by the trust of market leaders, driven by its expertise in hyaluronate production and impeccable quality control.

Lifecore (LFCR): Share Book Value from 04/28/2023 to 10/26/2026

Lifecore Biomedical Inc. - analytical breakdowns and key metrics (LFCR)

- price and consensus price forecast:

Stock Price Lifecore|LFCR - Consensus Target

- market capitalization data:

Market Value Lifecore Biomedical, Inc.|LFCR - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Lifecore Biomedical|LFCR - Net Asset Value|Market Capitalization to Book Value Ratio lifecore.com|LFCR - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Lifecore Biomedical|LFCR - Long-Term Debt to Capital|Short-Term Debt to Equity Lifecore|LFCR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lifecore Biomedical, Inc.

Fundamental company valuation:lifecore.com - LFCR

For Lifecore Biomedical (LFCR), whose resilience relies on strict FDA compliance and long-term sterile injectable contracts, net assets serve as an objective measure of the business's intrinsic value. Analyzing the book value per share allows for a comparison between the market price and actual capital minus liabilities, revealing the undervaluation of securities during periods of volatility and confirming the quality of the company's tangible asset base.

Competitors of Lifecore Biomedical (LFCR)